Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker.

Sulzbacher I, Birner P, Toma C, Wick N, Mazal PR.

J Clin Pathol. 2007 Jul;60(7):804-7. Epub 2006 Oct 3.

2.

Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas.

Entz-Werlé N, Marcellin L, Gaub MP, Guerin E, Schneider A, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone MD, Jeanne-Pasquier C, Terrier P, Dijoud F, Oudet P, Lutz P, Babin-Boilletot A.

J Clin Oncol. 2005 Apr 1;23(10):2248-55.

PMID:
15800315
3.

Expression of platelet-derived growth factor-alpha receptor and c-kit in giant cell tumours of bone.

Sulzbacher I, Dominkus M, Pichlhofer B, Mazal PR.

Pathology. 2009;41(7):630-3. doi: 10.3109/00313020903257749.

PMID:
20001342
4.

Expression of c-kit protein and mutational status of the c-kit gene in osteosarcoma and their clinicopathological significance.

Wei H, Zhao MQ, Dong W, Yang Y, Li JS.

J Int Med Res. 2008 Sep-Oct;36(5):1008-14.

PMID:
18831895
5.

Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.

Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F, Unni KK, Park YK.

Pathol Res Pract. 2007;203(3):127-34. Epub 2007 Feb 12.

PMID:
17298867
6.

C-kit expression in human osteosarcoma and in vitro assays.

Miiji LN, Petrilli AS, Di Cesare S, Odashiro AN, Burnier MN Jr, de Toledo SR, Garcia RJ, Alves MT.

Int J Clin Exp Pathol. 2011;4(8):775-81. Epub 2011 Nov 3.

7.

Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome.

Sulzbacher I, Birner P, Dominkus M, Pichlhofer B, Mazal PR.

Pathology. 2010 Dec;42(7):664-8. doi: 10.3109/00313025.2010.520310.

PMID:
21080877
8.

High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.

Knösel T, Chen Y, Altendorf-Hofmann A, Danielczok C, Freesmeyer M, Settmacher U, Wurst C, Schulz S, Yang LL, Petersen I.

J Cancer Res Clin Oncol. 2012 Mar;138(3):397-403. doi: 10.1007/s00432-011-1107-9. Epub 2011 Dec 8.

PMID:
22160160
9.

Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours.

Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y.

J Pathol. 2001 Apr;193(4):505-10.

PMID:
11276010
10.

Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series.

Gomes AL, Gouveia A, Capelinha AF, de la Cruz D, Silva P, Reis RM, Pimenta A, Lopes JM.

J Clin Pathol. 2008 Feb;61(2):203-8. Epub 2007 Sep 7.

11.

Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.

Boldrini L, Ursino S, Gisfredi S, Faviana P, Donati V, Camacci T, Lucchi M, Mussi A, Basolo F, Pingitore R, Fontanini G.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4101-8.

12.

Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.

Baumhoer D, Smida J, Specht K, Bink K, Quintanilla-Martinez L, Rosemann M, Siggelkow H, Nathrath WB, Atkinson MJ, Bielack S, Jundt G, Nathrath M.

Hum Pathol. 2011 Jun;42(6):859-66. doi: 10.1016/j.humpath.2010.09.016. Epub 2011 Feb 2.

PMID:
21292304
13.

Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.

Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A, Hagemeijer A, Sciot R.

J Pathol. 2004 Apr;202(4):430-8.

PMID:
15095270
14.

Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.

Lee HE, Kim MA, Lee HS, Lee BL, Kim WH.

J Clin Pathol. 2008 Jun;61(6):722-9. doi: 10.1136/jcp.2007.052225. Epub 2008 Apr 1.

PMID:
18381383
15.

Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors.

Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, Kim JS, Yook JH, Kim BS, Lee JS.

Clin Cancer Res. 2004 May 1;10(9):3076-81.

16.

Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.

Andersson J, Bümming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, Odén A, Gustavsson B, Kindblom LG, Nilsson B.

Gastroenterology. 2006 May;130(6):1573-81.

PMID:
16697720
17.

c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors.

Kinoshita K, Isozaki K, Hirota S, Nishida T, Chen H, Nakahara M, Nagasawa Y, Ohashi A, Shinomura Y, Kitamura Y, Matsuzawa Y.

J Gastroenterol Hepatol. 2003 Feb;18(2):147-51.

PMID:
12542597
18.

Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors.

Emile JF, Théou N, Tabone S, Cortez A, Terrier P, Chaumette MT, Julié C, Bertheau P, Lavergne-Slove A, Donadieu J, Barrier A, Le Cesne A, Debuire B, Lemoine A; Groupe d'Etude des GIST..

Clin Gastroenterol Hepatol. 2004 Jul;2(7):597-605.

PMID:
15224284
19.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA.

J Clin Oncol. 2003 Dec 1;21(23):4342-9.

PMID:
14645423
20.

Establishment and characterization of a KIT-positive and stem cell factor-producing cell line, KTHOS, derived from human osteosarcoma.

Hitora T, Yamamoto T, Akisue T, Marui T, Nakatani T, Kawamoto T, Nagira K, Yoshiya S, Kurosaka M.

Pathol Int. 2005 Feb;55(2):41-7.

PMID:
15693848

Supplemental Content

Support Center